241 related articles for article (PubMed ID: 10415026)
1. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
2. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
[TBL] [Abstract][Full Text] [Related]
3. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells require maturation via CD40 to generate protective antitumor immunity.
Mackey MF; Gunn JR; Maliszewsky C; Kikutani H; Noelle RJ; Barth RJ
J Immunol; 1998 Sep; 161(5):2094-8. PubMed ID: 9725199
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
Nakajima A; Kodama T; Morimoto S; Azuma M; Takeda K; Oshima H; Yoshino S; Yagita H; Okumura K
J Immunol; 1998 Aug; 161(4):1901-7. PubMed ID: 9712059
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF.
Daro E; Butz E; Smith J; Teepe M; Maliszewski CR; McKenna HJ
Cytokine; 2002 Feb; 17(3):119-30. PubMed ID: 11895330
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of intestinal Peyer's patch interferon-alpha producing (plasmacytoid) dendritic cells.
Castellaneta A; Abe M; Morelli AE; Thomson AW
Hum Immunol; 2004 Feb; 65(2):104-13. PubMed ID: 14969765
[TBL] [Abstract][Full Text] [Related]
10. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway.
Ashany D; Savir A; Bhardwaj N; Elkon KB
J Immunol; 1999 Nov; 163(10):5303-11. PubMed ID: 10553053
[TBL] [Abstract][Full Text] [Related]
12. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
13. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.
Labeur MS; Roters B; Pers B; Mehling A; Luger TA; Schwarz T; Grabbe S
J Immunol; 1999 Jan; 162(1):168-75. PubMed ID: 9886383
[TBL] [Abstract][Full Text] [Related]
14. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.
Mosca PJ; Hobeika AC; Colling K; Clay TM; Thomas EK; Caron D; Lyerly HK; Morse MA
J Leukoc Biol; 2002 Sep; 72(3):546-53. PubMed ID: 12223523
[TBL] [Abstract][Full Text] [Related]
15. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.
Saito T; Takayama T; Osaki T; Nagai S; Suzuki T; Sato M; Kuwano H; Tahara H
Cancer Sci; 2008 Oct; 99(10):2028-36. PubMed ID: 19016763
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2004; 24(5A):2713-6. PubMed ID: 15517876
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154.
Mackey MF; Gunn JR; Ting PP; Kikutani H; Dranoff G; Noelle RJ; Barth RJ
Cancer Res; 1997 Jul; 57(13):2569-74. PubMed ID: 9205055
[TBL] [Abstract][Full Text] [Related]
18. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
19. Modulating dendritic cells to optimize mucosal immunization protocols.
Williamson E; Westrich GM; Viney JL
J Immunol; 1999 Oct; 163(7):3668-75. PubMed ID: 10490961
[TBL] [Abstract][Full Text] [Related]
20. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.
Sang H; Pisarev VM; Chavez J; Robinson S; Guo Y; Hatcher L; Munger C; Talmadge CB; Solheim JC; Singh RK; Talmadge JE
Cancer Gene Ther; 2005 Apr; 12(4):427-37. PubMed ID: 15678151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
